Elasmogen: Targeting cytotoxic immunity for the resolution of neuropathic pain

Targeting the pathogenic Th17 cell axis in autoimmunity:developing a portfolio of novel.

1 Dec 2021 · £1.58m · UKRI FLF

CageTag: Caged Theranostics as a Universal Platform for Nuclear Medicine

1 Apr 2022 · EPSRC

SSA Uncovering the pharmacology of a novel receptor target

1 Oct 2018 · BBSRC

Bridging critical funding gap to deliver late-stage pre-clinical oncology assets

1 Jun 2020 · £232k · Innovate UK

Enabling enhanced preclinical nuclear imaging at the University of Hull

31 Oct 2022 · MRC

University of Aberdeen and Elasmogen Limited

1 Dec 2018 · Innovate UK

Finding Needles in Haystacks: First-in-class soloMER drug candidates as precision medicine for autoimmune inflammation diseases.

1 Dec 2025 · £528k · UKRI FLF

Development of intracellular VNARs as novel tools to dissect intracellular biological processes

1 Apr 2018 · BBSRC

Uncovering the pharmacology of a novel receptor target for age-related macular degeneration

1 Oct 2018 · BBSRC

soloMER™ Biologics: Next-generation therapeutics for the site-specific treatment of ocular diseases

1 Feb 2017 · £686k · Innovate UK

A Technology Platform for Next Generation VNAR Based Oncology Medicines

1 Aug 2018 · Innovate UK

Queen's university Belfast and Elasmogen Limited

1 Nov 2019 · Innovate UK